检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:陈莉娜[1] 朱春梅[2] 李硕[2] 陈育智[2]
机构地区:[1]四川大学华西第二医院儿科,成都610041 [2]首都儿科研究所哮喘防治中心
出 处:《现代预防医学》2008年第14期2796-2797,2799,共3页Modern Preventive Medicine
摘 要:[目的]观察吸入布地奈德福莫特罗干粉剂治疗中、重度儿童哮喘的疗效和安全性。[方法]37例中重度发作哮喘儿童给予布地奈德福莫特罗吸入治疗3个月,重度组短期加用口服泼尼松及缓释沙丁胺醇等对症治疗,观察治疗后2周~1月、3月时的肺功能变化、症状改善情况及不良反应。[结果]37例患儿治疗后肺功能FEV1、FEV1%、FVC、FVC%、PEF、PEF%、MMEF、MMEF%等各项指标较治疗前明显改善(P﹤0.05);症状平均缓解时间为3~4d;治疗后2周91.2%患儿症状得到完全控制,治疗1月、2月及3月时完全控制率为100%;3月内无1例患儿需急诊就医或吸入短效β2激动剂缓解症状;不良反应为声嘶、咽部不适。[结论]布地奈德福莫特罗治疗儿童中重度持续性哮喘有良好的疗效和安全性。[Objective] To observe efficacy and safety of budesonide/formoterol in the treatment of children with moderate or severe asthma. [ Methods] 37 children with moderate or severe asthma were treated with budesonide/formoterol for 3 months. Oral prednisone and slow release salbutamol were given to children with severe asthmatic. Lung function, symptom improvements and adverse effects were observed after treatment at the time of two weeks, one month and three months. [Results] Such lung function indexes as FEV1, FEV1%, FVC, FVC%, PEF, PEF%, MMEF and MMEF% of 37 children with asthma were showed to be significantly improved 2 weeks to 1 month and 3 months post treatment (P 〈 0.05) : The average time for relieving of symptom was 3 to 4 days. 91.2% of the children gained complete control after 2 weeks. The complete control rates for children with asthma affter treating for one, two and three months were 100% ; children gained complete control at 1 month, 2 months and 3 months post treatment. No child showed to be emergency treatment and short-acting β2 agonist inhalation in three months after treatment. Some adverse effects were observed including hoarseness and pharyngeal discomfort. [ Conclusion] Budesonide/formoterol showed to be effective and safe for children with moderate or severe asthma.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.249